Latest filings (excl ownership)
EFFECT
Notice of effectiveness
2 May 24
424B3
Prospectus supplement
1 May 24
S-3
Shelf registration
22 Apr 24
10-K/A
2023 FY
Annual report (amended)
17 Apr 24
8-K
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
9 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
S-8
Registration of securities for employees
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territory
21 Mar 24
DEF 14A
Definitive proxy
15 Mar 24
8-K
Unregistered Sales of Equity Securities
8 Mar 24
PRE 14A
Preliminary proxy
5 Mar 24
8-K
Entry into a Material Definitive Agreement
1 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Feb 24
8-K
Entry into a Material Definitive Agreement
1 Dec 23
D
$60.00 k in equity / Common Stock, sold $60.00 k, 1 investor
30 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq’s Bid Price Rule
8 Nov 23
8-K
Entry into a Material Definitive Agreement
5 Oct 23
S-8
Registration of securities for employees
14 Aug 23
8-K
Jaguar Health Reports Second Quarter 2023 Financial Results
14 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Jaguar Health Reports Approval of All Proposals at 2023 Annual Meeting of Stockholders
7 Jul 23
8-K
Entry into a Material Definitive Agreement
3 Jul 23
ARS
2022 FY
Annual report to shareholders
31 May 23
DEF 14A
Definitive proxy
31 May 23
8-K
Departure of Directors or Certain Officers
19 May 23
PRE 14A
Preliminary proxy
16 May 23
S-8
Registration of securities for employees
15 May 23
8-K
Jaguar Health Reports First Quarter 2023 Financial Results
15 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 May 23
D
$1.83 mm in equity / options, sold $1.83 mm, 3 investors
11 May 23
D
$1.86 mm in equity / options, sold $1.86 mm, 6 investors
11 May 23
8-K
Jaguar Completes Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
9 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
S-8
Registration of securities for employees
6 Apr 23
8-K
Jaguar Health Reports 2022 Financial Results – Prescription Revenues up 179% to $11.9 Million
27 Mar 23
10-K
2022 FY
Annual report
24 Mar 23
8-K
Other Events
8 Feb 23
Latest ownership filings
4
Pravin R Chaturvedi
17 Apr 24
4
Jonathan S. Wolin
17 Apr 24
4
Carol R. Lizak
17 Apr 24
4
Steven R. King
17 Apr 24
4
LISA A CONTE
17 Apr 24
SC 13G
Iliad Research & Trading, L.P.
29 Dec 23
4
Anula Jayasuriya
14 Aug 23
4
Jonathan B. Siegel
14 Aug 23
4
JOHN MICEK
14 Aug 23
4
JAMES J BOCHNOWSKI
14 Aug 23
4
Pravin R Chaturvedi
14 Aug 23
4
Jonathan S. Wolin
14 Aug 23
4
Carol R. Lizak
14 Aug 23
4
Steven R. King
14 Aug 23
4
LISA A CONTE
14 Aug 23
SC 13G
Fife John M.
13 Jul 23
4
Pravin R Chaturvedi
19 May 23
4/A
Pravin R Chaturvedi
19 May 23
4/A
Pravin R Chaturvedi
19 May 23
4
Jonathan B. Siegel
19 May 23
4
JOHN MICEK
19 May 23
4
JAMES J BOCHNOWSKI
19 May 23
4
Jonathan S. Wolin
19 May 23
4
Carol R. Lizak
19 May 23
4
Steven R. King
19 May 23
4
LISA A CONTE
19 May 23
4
Pravin R Chaturvedi
20 Apr 23
4
Carol R. Lizak
20 Apr 23
4
Jonathan S. Wolin
20 Apr 23
4
Steven R. King
20 Apr 23
4
LISA A CONTE
20 Apr 23
4
Anula Jayasuriya
6 Apr 23
SC 13G/A
Mailman Joshua
23 Feb 23
SC 13G/A
Mailman Joshua
14 Feb 23
4
Jonathan S. Wolin
3 Jan 23
4
Pravin R Chaturvedi
28 Dec 22
4
Jonathan S. Wolin
28 Dec 22
4
Carol R. Lizak
28 Dec 22
4
Steven R. King
28 Dec 22
4
LISA A CONTE
28 Dec 22